牛牛AI助理已提取核心訊息
TransCode Therapeutics, Inc., a biotechnology company, held a Special Meeting of Stockholders on January 8, 2024. During the meeting, stockholders voted on two key proposals. The first proposal was to approve an amendment for a reverse stock split of the company's common stock, with a ratio ranging from 1-for-10 to 1-for-40, at the discretion of the Board of Directors. The second proposal was to approve the adjournment of the Special Meeting if there were insufficient votes to pass the reverse stock split. Both proposals were described in the Company’s Definitive Proxy Statement filed on December 18, 2023. The total number of shares entitled to vote was 25,097,596, with 12,472,113 shares present or represented by proxy. The Reverse Stock Split Proposal received 7,081,896 votes for, 5,348,629 against, and 41,588 abstentions. The Adjournment Proposal received 7,426,024 votes for, 4,836,062 against, and 210,027 abstentions. Both proposals were approved by the stockholders, and no adjournment was necessary as the reverse stock split proposal passed without requiring additional votes.
TransCode Therapeutics, Inc., a biotechnology company, held a Special Meeting of Stockholders on January 8, 2024. During the meeting, stockholders voted on two key proposals. The first proposal was to approve an amendment for a reverse stock split of the company's common stock, with a ratio ranging from 1-for-10 to 1-for-40, at the discretion of the Board of Directors. The second proposal was to approve the adjournment of the Special Meeting if there were insufficient votes to pass the reverse stock split. Both proposals were described in the Company’s Definitive Proxy Statement filed on December 18, 2023. The total number of shares entitled to vote was 25,097,596, with 12,472,113 shares present or represented by proxy. The Reverse Stock Split Proposal received 7,081,896 votes for, 5,348,629 against, and 41,588 abstentions. The Adjournment Proposal received 7,426,024 votes for, 4,836,062 against, and 210,027 abstentions. Both proposals were approved by the stockholders, and no adjournment was necessary as the reverse stock split proposal passed without requiring additional votes.
生物技術公司TransCode Therapeutics, Inc. 於2024年1月8日舉行了股東特別會議。會議期間，股東對兩項關鍵提案進行了投票。第一項提案是批准公司普通股反向拆分的修正案，比例從1比10到1比40不等，由董事會自行決定。第二項建議是，如果沒有足夠的選票通過反向股票分割，則批准特別會議休會。公司於2023年12月18日提交的最終委託書中描述了這兩項提案。有權投票的股票總數爲25,097,596股，其中12,472,113股股票由代理人出席。反向股票拆分提案獲得了7,081,896張贊成票，5,348,629張反對票，41,588張棄權票。休會提案獲得7,426,024張贊成票，4,836,062張反對票，210,027張棄權票。這兩項提案都得到了股東的批准，沒有必要休會，因爲反向股票拆分提案在不需要額外投票的情況下獲得通過。
生物技術公司TransCode Therapeutics, Inc. 於2024年1月8日舉行了股東特別會議。會議期間，股東對兩項關鍵提案進行了投票。第一項提案是批准公司普通股反向拆分的修正案，比例從1比10到1比40不等，由董事會自行決定。第二項建議是，如果沒有足夠的選票通過反向股票分割，則批准特別會議休會。公司於2023年12月18日提交的最終委託書中描述了這兩項提案。有權投票的股票總數爲25,097,596股，其中12,472,113股股票由代理人出席。反向股票拆分提案獲得了7,081,896張贊成票，5,348,629張反對票，41,588張棄權票。休會提案獲得7,426,024張贊成票，4,836,062張反對票，210,027張棄權票。這兩項提案都得到了股東的批准，沒有必要休會，因爲反向股票拆分提案在不需要額外投票的情況下獲得通過。
有用
沒用